[HER2]

Jinyu Yu1,2, Baoshan Cao1,2

  • 1Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing 100191, China.

概括

在非小细胞肺癌 (NSCLC) 中,针对人类表皮生长因子受体2 (HER2) 突变的向疗法显示出有前途. 研究正在朝着组合策略和理解抵抗机制的方向进行,以改善个性化治疗.

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K